Biodexa Pharmaceticals (BDRX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.74 (-7.64%), Market cap $0.00B, 52-week low–high $0.61 ~ $10.90.
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTX240, for the treatment of gastrointestinal stromal tumors. In addition, the company offers drug delivery pl
Financial statements, price targets, institutional (13F) holdings and related news for Biodexa Pharmaceticals are updated in real time on BlackAll Trade.
Biodexa Pharmaceticals trades at $0.74 (-7.64%). Real-time quotes and charts are available on BlackAll Trade.
Biodexa Pharmaceticals has a market cap of about $0.00B.
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder c